• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Invacare Corporation

    8/14/23 5:13:37 PM ET
    $IVC
    Industrial Specialties
    Health Care
    Get the next $IVC alert in real time by email
    NT 10-Q 1 form12b-25_2q23x10xq.htm NT 10-Q Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 12b-25
    NOTIFICATION OF LATE FILING
    (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

    For Period Ended: June 30, 2023

    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
    ☐ Transition Report on Form N-SAR

    For the Transition Period Ended: ________________________

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

    If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

    PART I -- REGISTRANT INFORMATION

    Invacare Holdings Corporation
    Full Name of Registrant

    Invacare Corporation
    Former Name if Applicable

    One Invacare Way
    Address of Principal Executive Office (Street and Number)

    Elyria, Ohio 44035
    City, State and Zip Code

    PART II -- RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

    (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☐
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.









    PART III -- NARRATIVE

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    Invacare Holdings Corporation (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Form 10-Q”) within the prescribed time period due to the Company’s emergence from bankruptcy on May 5, 2023 (the “Emergence Date”), and the extra time necessary to prepare financial statements and disclosures which apply fresh start accounting as required in the Form 10-Q. The delay in preparing the reported financial statements and related disclosures is principally related to the requirement of fresh start accounting under which the Company must establish a new successor reporting entity, break down its current reporting period between predecessor and successor periods, and determine new fair values for the new reporting entity’s assets, liabilities and equity as of the Emergence Date, which cannot be completed prior to the prescribed due date for the Form 10-Q without unreasonable effort or expense.

    The Company will work diligently to file the Form 10-Q, but cannot currently predict or provide assurance as to the date on which the Form 10-Q will be filed.

    PART IV -- OTHER INFORMATION

    (1) Name and telephone number of person to contact in regard to this notification


        Kai Zhu                   (440)          329-6000
    (Name)             (Area Code)         (Telephone Number)

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

    ☒ Yes ☐ No

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

    ☒ Yes ☐ No

    As described above in Part III – Narrative to this Form 12b-25, the Company was unable to file its Form 10-Q within the prescribed time period without unreasonable effort and expense. The Company’s results of operations for the three and six month periods ended June 30, 2023 will not be comparable to the corresponding prior year due to fresh start accounting.

    Due to the delay in finalizing certain financial and other related date in the Form 10-Q, the Company’s results of operations for the period ending June 30, 2023 have not been finalized. As a result, the Company is currently unable to provide a reasonable estimate of certain of the results or the anticipated changes from prior period results.

    Invacare Holdings Corporation
    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

    Date: August 14, 2023                    By: /s/ Kai Zhu        
    Kai Zhu
    Senior Vice President, Chief Financial Officer

    Get the next $IVC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVC

    DatePrice TargetRatingAnalyst
    10/29/2021$11.00 → $9.00Outperform
    Oppenheimer
    9/10/2021$17.00 → $8.00Buy
    Needham
    8/19/2021$11.00Outperform
    Oppenheimer
    More analyst ratings

    $IVC
    SEC Filings

    See more
    • Invacare Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - INVACARE HOLDINGS Corp (0000742112) (Filer)

      2/16/24 5:16:23 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • SEC Form NT 10-Q filed by Invacare Corporation

      NT 10-Q - INVACARE HOLDINGS Corp (0000742112) (Filer)

      11/15/23 4:06:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits

      8-K - INVACARE HOLDINGS Corp (0000742112) (Filer)

      9/13/23 4:31:43 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Invacare Corporation Takes Action to Strengthen Its Financial Position and Drive Long-Term Growth Through Voluntary Prearranged Chapter 11 Cases That Do Not Include Its International Operations

      Refinancing action will reduce net debt by approximately 65% Global manufacturing and delivery of products to continue uninterrupted to meet robust customer demand Strong sequential improvement achieved in preliminary 4Q22 financial results Executed strategic actions accelerating a renewed focus on core businesses Invacare Corporation (NYSE:IVC) ("Invacare" or "the company"), a leading manufacturer and distributor of medical equipment used in non-acute care settings, today announced actions to strengthen the company and position it for long-term success. To facilitate its financial restructuring, the company has entered into a Restructuring Support Agreement (the "RSA" or "Agreement")

      2/1/23 8:33:00 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation Announces Additional Draw of Term Loans

      Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") announced the consummation of an additional draw of $5,500,000 of term loans under to its Credit Agreement with certain funds managed by Highbridge Capital Management LLC ("Highbridge"), as of December 23, 2022. Commenting on the financing, Geoff Purtill, president and chief executive officer stated, "As guided in the 3Q22 earnings release, Europe achieved sequential growth in revenues and profitability driven by improved supply chain circumstances giving us confidence that our transformation program is reaping benefits. Today's announcement provides us with greater flexibility as we execute against our stated strategy. We are p

      12/27/22 8:02:00 AM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Financials

    Live finance-specific insights

    See more
    • Invacare Reports Results for Third Quarter 2022

      Updates strategic priorities with the discontinuation of the production of respiratory products Anticipates sequential improvement in revenues and profitability in 4Q22 Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") today reported results for the quarter ended September 30, 2022. Executive Summary Reflecting on the quarter and the company's progress against its transformation program, Geoffrey Purtill, interim president and chief executive officer, said "We remain committed to taking necessary and decisive action to increase shareholder value. After carefully evaluating our strategic options, we have determined that the lifestyle and mobility & seating categories are core

      11/7/22 4:15:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results

      Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") announces that it will release its financial results for the third quarter ended September 30, 2022, after the market closes on Monday, November 7, 2022. The company will provide a live conference call and webcast to discuss these financial results on Tuesday, November 8, 2022, at 8:30 AM ET. Investors and other interested parties may access the webcast and conference call in the following ways: Those wishing to participate via webcast can register and access the event at https://events.q4inc.com/attendee/918973030 Those wishing to participate via telephone can dial 844-200-6205 (U.S. and Canada) or 929-526-1599 (internation

      10/20/22 8:00:00 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Reports Results for Second Quarter 2022

      Achieved sequential improvement in profitability and free cash flow Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") today reported results for the quarter ended June 30, 2022. Executive Summary Reflecting on the quarter, Matt Monaghan, chairman, president, and chief executive officer, said "In 2Q22, we achieved sequential revenue growth of 4.7% in mobility & seating products driven by increased adoption of our compelling product portfolio. We continue to experience elevated backlog across all product categories and regions, and see strong demand in mobility & seating and lifestyle products. We are working diligently to increase output and convert order backlog into sales.

      8/8/22 4:20:00 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Davidson Kempner Capital Management Lp claimed ownership of 717,650 shares (SEC Form 3)

      3 - INVACARE HOLDINGS Corp (0000742112) (Issuer)

      2/12/24 4:15:59 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Ferreira Cintia was granted 84,000 shares (SEC Form 4)

      4 - INVACARE HOLDINGS Corp (0000742112) (Issuer)

      11/3/23 5:15:51 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Purtill Geoffrey was granted 1,204,000 shares (SEC Form 4)

      4 - INVACARE HOLDINGS Corp (0000742112) (Issuer)

      11/3/23 5:13:41 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Invacare Appoints Geoff Purtill President and Chief Executive Officer

      Invacare Corporation (NYSE:IVC) announced today that its Board of Directors has named Geoffrey P. Purtill as President and Chief Executive Officer, roles that he has served on an interim basis since August 28, 2022. Non-executive Chairman of the Board of Directors Michael J. Merriman, Jr, said, "On behalf of the Board, we are excited to elevate Geoff Purtill into the role of President and CEO. The Board determined that Geoff is the right steward of the company as it undergoes significant transformation and embarks on a new chapter. Geoff has proven adept at guiding our global businesses through change, both in his previous role overseeing the EMEA and APAC businesses, and now in his curren

      11/21/22 5:03:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation Announces Executive Leadership Changes

      Appoints Geoff Purtill as Interim Chief Executive Officer and Michael Merriman as Board Chairman Invacare Corporation (NYSE:IVC) today announced changes to its senior management team and Board of Directors to advance its previously announced business transformation initiatives, address supply chain challenges, and strengthen its financial performance. Geoffrey P. Purtill, who had been serving as the company's Senior Vice President and General Manager, EMEA and APAC, was named interim President and Chief Executive Officer, replacing Matthew E. Monaghan, who has left from his role as Chairman, President and Chief Executive Officer, effective August 28, 2022. The Board of Directors has comme

      8/29/22 7:35:00 AM ET
      $AM
      $IVC
      $NDSN
      $RGS
      Natural Gas Distribution
      Utilities
      Industrial Specialties
      Health Care

    $IVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

      SC 13D/A - INVACARE HOLDINGS Corp (0000742112) (Subject)

      2/15/24 9:03:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

      SC 13D/A - INVACARE HOLDINGS Corp (0000742112) (Subject)

      2/15/24 9:00:49 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

      SC 13D/A - INVACARE HOLDINGS Corp (0000742112) (Subject)

      2/15/24 9:00:18 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer reiterated coverage on Invacare with a new price target

      Oppenheimer reiterated coverage of Invacare with a rating of Outperform and set a new price target of $9.00 from $11.00 previously

      10/29/21 7:39:40 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Needham reiterated coverage on Invacare with a new price target

      Needham reiterated coverage of Invacare with a rating of Buy and set a new price target of $8.00 from $17.00 previously

      9/10/21 5:41:14 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Oppenheimer initiated coverage on Invacare with a new price target

      Oppenheimer initiated coverage of Invacare with a rating of Outperform and set a new price target of $11.00

      8/19/21 7:41:53 AM ET
      $IVC
      Industrial Specialties
      Health Care